Member Info for ogm4

Great letter of confidence by CEO informing / reassuring shareholders this morning!.... ;-)

Omwards and upwards.

Atb

Kali and Sanofi sign licence agreement for KT501 autoimmune disease antibody

Under the agreement, Kali Therapeutics is set to receive $180m in upfront and near-term payments.

Salong Debbarma

March 24, 2026

https://www.pharmaceutical-technology.com/news/kali-sanofi-licence-agreement-kt501/

180MM USD upfront

Roughly:

90% FOR

10% AGAINST

for both resolutions individually

Massive vote of confidence!!...

Onwards and upwards.

Over £6 Million pounds extra in the bank!

Bring on P140 AND Kapiglucagon!

The General Meeting is scheduled to be held at 11.00 a.m. (GMT) on 7 April 2026, at the offices of Broadfield Law UK LLP, One Bartholomew Close, London EC1A 7BL.

To my understanding (correct me if I am wrong) in the UK a patent can be granted in 9-12 months after the filing date provided a Combined Search and Examination Report (CSER) is used (accelerated process). If also no objections were raised by the UKIPO and taking into account a mandatory waiting period after publication of 3 months then we could be only a few months away from obtaining patent grant.

"The scientific team, led by Dr Sébastien Goudreau, CSO, and Dr Laura Mauran, Head of R&D, is preparing a scientific manuscript describing the P140 technology platform and its mechanism of action, including recent supporting data. The Company intends to submit the manuscript to a peer-reviewed journal in due course. Following publication, the findings will be shared more broadly with the scientific community."

Immupharma is much more than our CEO Tim only. There is a dedicated scientific team behind it making structural progress along the way.

Today's announcement regarding the positive CSER response are well on track and should not be underestimated:

"The Company has received a first Combined Search and Examination Report ("CSER") in relation to its United Kingdom patent application for P140, filed in September 2025. The supportive response is as expected by management at this stage of the patent examination process and represents an important positive milestone in the ongoing progress of the application."

A Combined Search and Examination Report (CSER) represents a combined document issued by the UK Intellectual Property Office (IPO) by integrating two stages of the patent process to accelerate the process for increased efficiency.

Goal: To accelerate the patent process by providing an early indication to state if the proposed invention is indeed new and inventive.

In fact today's announcement is another milestone for IMM as such really.

Publication of the P140 results within the wider pharma industry and scientific community will be the next step.

We might end up blue today after this nice unexpected update this morning.

As Tim mentioned last week lots of news flow coming this year!

Great to see the team is progressing on multiple fronts.

Great detailed update on P140 and pending patent this morning!

Very constructive update to shareholders I must admit.

Https://www.reuters.com/business/healthcare-pharmaceuticals/kali-therapeutics-signs-deal-with-sanofi-develop-autoimmune-treatment-2026-03-23/

Gilead Sciences buys autoimmune biotech Ouro Medicines for $2.2bn

California-based drugmaker takes advantage of surging share price to strike takeovers

Oliver Barnes in New York

Publishedyesterday

Updated 00:24

https://www.ft.com/content/81528c31-c735-41b7-b042-81a811a76877?syn-25a6b1a6=1

No more cash concerns until at least H2 2028

Two flagships in development

P140

Kapiglucagon

Kapiglucagon internal sales forecast is indeed 3 Billion USD revenue for Immupharma for 10 yrs post approval period.

Note: Kapiglucagon represents a fully proprietary asset owned by ImmuPharma, with 100% of the intellectual property held by the company.

Indeed as stated by the CSO there was no pushback so far from any of the potential partners on P140.

I read that as a big positive.

* Kapiglucagon is absolute superior to any other similar product currently out there on the market

* Kapiglucagon would be the only 'go to' product in near future.

* Bihormonal pumps are the future preferred above other conventional methods

* 3 Billion USD Annual sales potential for IMM (conservative estimate)

Feeling more confident now again

The live presentation, via the 'Investor Meet Company' platform, will be held on Friday 20 March 2026 @ 12:00 (GMT).

Tim McCarthy, CEO, Dr Sébastien Goudreau, CSO, and Dr Tim Franklin, COO, will provide a live presentation relating to the Company's announcement, released on Tuesday 17 March 2026